These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 16146813)
1. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Preusser M; Wolfsberger S; Czech T; Slavc I; Budka H; Hainfellner JA Am J Clin Pathol; 2005 Oct; 124(4):543-9. PubMed ID: 16146813 [TBL] [Abstract][Full Text] [Related]
2. No prognostic impact of survivin expression in glioblastoma. Preusser M; Gelpi E; Matej R; Marosi C; Dieckmann K; Rössler K; Budka H; Hainfellner JA Acta Neuropathol; 2005 May; 109(5):534-8. PubMed ID: 15843906 [TBL] [Abstract][Full Text] [Related]
3. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327 [TBL] [Abstract][Full Text] [Related]
4. Topoisomerase IIalpha expression as an independent prognostic factor in Hodgkin's lymphoma. Doussis-Anagnostopoulou IA; Vassilakopoulos TP; Thymara I; Korkolopoulou P; Angelopoulou MK; Siakantaris MP; Kokoris SI; Dimitriadou EM; Kalpadakis C; Matzouranis M; Kaklamanis L; Panayiotidis P; Kyrtsonis MC; Androulaki A; Patsouris E; Kittas C; Pangalis GA Clin Cancer Res; 2008 Mar; 14(6):1759-66. PubMed ID: 18347177 [TBL] [Abstract][Full Text] [Related]
5. Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Ikehara M; Oshita F; Kameda Y; Ito H; Ohgane N; Suzuki R; Saito H; Yamada K; Noda K; Mitsuda A Oncol Rep; 2002; 9(4):835-8. PubMed ID: 12066218 [TBL] [Abstract][Full Text] [Related]
6. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513 [TBL] [Abstract][Full Text] [Related]
7. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980 [TBL] [Abstract][Full Text] [Related]
8. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Wolfsberger S; Fischer I; Höftberger R; Birner P; Slavc I; Dieckmann K; Czech T; Budka H; Hainfellner J Am J Surg Pathol; 2004 Jul; 28(7):914-20. PubMed ID: 15223962 [TBL] [Abstract][Full Text] [Related]
9. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Preusser M; Heinzl H; Gelpi E; Höftberger R; Fischer I; Pipp I; Milenkovic I; Wöhrer A; Popovici F; Wolfsberger S; Hainfellner JA Histopathology; 2008 Jul; 53(1):39-47. PubMed ID: 18613924 [TBL] [Abstract][Full Text] [Related]
10. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252 [TBL] [Abstract][Full Text] [Related]
11. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Holden JA; Townsend JJ Mod Pathol; 1999 Dec; 12(12):1094-100. PubMed ID: 10619260 [TBL] [Abstract][Full Text] [Related]
12. Tumor vessel biology in pediatric intracranial ependymoma. Wagemakers M; Sie M; Hoving EW; Molema G; de Bont ES; den Dunnen WF J Neurosurg Pediatr; 2010 Apr; 5(4):335-41. PubMed ID: 20367336 [TBL] [Abstract][Full Text] [Related]
13. Survivin expression and its relationship with apoptosis and prognosis in nasal and paranasal sinus carcinomas. Zhang Y; Huang D; Yu G Acta Otolaryngol; 2005 Dec; 125(12):1345-50. PubMed ID: 16303685 [TBL] [Abstract][Full Text] [Related]
14. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Zhen HN; Zhang X; Hu PZ; Yang TT; Fei Z; Zhang JN; Fu LA; He XS; Ma FC; Wang XL Cancer; 2005 Dec; 104(12):2775-83. PubMed ID: 16284993 [TBL] [Abstract][Full Text] [Related]
15. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Kleinberg L; Flørenes VA; Silins I; Haug K; Trope CG; Nesland JM; Davidson B Cancer; 2007 Jan; 109(2):228-38. PubMed ID: 17167759 [TBL] [Abstract][Full Text] [Related]
16. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype. Suri VS; Tatke M; Singh D; Sharma A Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011 [TBL] [Abstract][Full Text] [Related]
17. Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. Kogiku M; Ohsawa I; Matsumoto K; Sugisaki Y; Takahashi H; Teramoto A; Ohta S J Clin Neurosci; 2008 Nov; 15(11):1198-203. PubMed ID: 18835716 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions. Mattila R; Alanen K; Syrjänen S Arch Dermatol Res; 2007 Jan; 298(8):381-8. PubMed ID: 17072627 [TBL] [Abstract][Full Text] [Related]
19. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Nasr MR; El-Zammar O Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113 [TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 (cox-2) expression and angiogenesis in intracranial ependymomas. Onguru O; Kurt B; Gunhan O; Soylemezoglu F Clin Neuropathol; 2006; 25(5):216-20. PubMed ID: 17007443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]